Form D · Biotechnology
Rebalance Health, Inc.
Boulder, CO · CIK 0001869786
Offering snapshot reported Aug 28, 2023 · SEC filing
- Reported sold
- $7.37M Offering amount: $10M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 28, 2023 | Initial | $7,371,448 | No comparison | 39 | SEC filing |
| May 13, 2022 | Initial | $7,630,672 | No comparison | 68 | SEC filing |
| Nov 9, 2021 | Amendment | $6,699,999 | $2,450,020vs Aug 4, 2021 | 96 | SEC filing |
| Aug 4, 2021 | Initial | $4,249,979 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-490828
Source: Form D, filed Aug 28, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James B. Breitmeyer | Director |
| James Breitmeyer, M.D., Ph.D. | Director |
| Scott L. Glenn | Director, Executive |
| Justin A. Hai | Director, Executive |
| Randy Hetrick | Director |
| Patrick A. Hopf | Director |
| Charles Kloeris | Director, Executive |
| Mark C. Mc Kenna | Director |
| Fabian Seelbach | Director |
| Fabian Sellbach | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1855 57th Court South
Boulder, CO, 80301
Boulder, CO, 80301